Colon Cancer Liquid Biopsy Investigation of Methylation-based Biomarkers Evaluation Using Delta-HLD (CLIMBED)
Clinical Validation Cross-sectional Study for Colorectal Cancer Assessment Using Delta-HLD Technology (CLIMBED)
Epiliquid Holding, Inc
3,200 participants
Apr 4, 2024
OBSERVATIONAL
Conditions
Summary
CLIMBED (Colon cancer Liquid biopsy Investigation of Methylation-based Biomarkers Evaluation using Delta-HLD) is a non-randomized, observational, cross-sectional clinical validation study designed to assess the performance of Delta-HLD, Epiliquid's proprietary liquid biopsy technology, for colorectal cancer (CRC) detection. The study will evaluate the test performance in an average-risk population for CRC undergoing screening colonoscopy, which will serve as the gold standard reference.
Eligibility
Inclusion Criteria2
- Men and women aged 45-75 years
- Indication of colorectal cancer screening colonoscopy by treating physician
Exclusion Criteria6
- First-degree family history of CRC
- Inflammatory bowel disease (ulcerative colitis, Crohn's disease)
- Other malignancies within 5 years
- Known hereditary CRC syndromes (Lynch, FAP)
- Major trauma, surgery, transfusion in past 30 days
- Current participation in an interventional clinical trial
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07168876